Projects

NovaMedica Pharmaceutical Plant, Kaluga

In May 2017, NovaMedica began constructing a new pharmaceutical manufacturing plant for sterile injectable drugs in Vorsino Industrial Park, Kaluga, Russia.

Project Type
Pharmaceutical manufacturing plant
Location
Vorsino industrial park, Kaluga Region, Russia
Construction Started
May 2017
Expected Completion
2020
Estimated Investment
RUR3bn (approximately $41.7m)
Operator
NovaMedica
Investor
Pfizer

In May 2017, NovaMedica began constructing a new pharmaceutical manufacturing plant for sterile injectable drugs in Vorsino Industrial Park, Kaluga, Russia.

NovaMedica is a joint venture (JV) of RUSNANO and Domain Associates. It is building the plant under a strategic partnership agreement signed with Pfizer in July 2016 that allows it to localise foreign pharmaceutical innovations in Russia.

NovaMedica signed a special investment contract (SPIC) with the Ministry of Industry and Trade of the Russian Federation and the Kaluga Region in March 2018. The investor will be responsible for development of the project, while the government provides stable regulations and incentives.

The SPIC will enable NovaMedica to invest more than RUR3bn ($41.7m) in the project and create 300 high-tech jobs. It will enable NovaMedica to export approximately 20% of the products manufactured to global markets.

The construction of the new pharmaceutical plant is expected to be completed in 2020 and full-scale production is scheduled to begin in 2023.

NovaMedica’s new plant construction

NovaMedica unveiled its plans to establish the new manufacturing plant in the Kaluga region in 2016. The project involves the creation of isolated production units for manufacturing standard and cytostatic drugs.

“The plant is designed to produce more than 38.5 million cartridge and vial units a year.”

The new plant will produce 30 Pfizer-owned pharmaceuticals in the form of sterile injections for the local market. The products will meet the good manufacturing practice (GMP) standards of Russia, Europe and Asia, as well as the US Food and Drug Administration (FDA).

The engineering work was concluded by the first half of 2017, while construction of the manufacturing complex is currently in progress.

NovaMedica’s Kaluga plant design

The plant is designed to produce more than 38.5 million cartridge and vial units a year. It will occupy an area of 23,00m², featuring sites for the preparation of sterile injections, lyophilisation and solutions in vials and cartridges.

Manufacturing lines in the plant will be equipped with production amenities similar to those used by major European manufacturing companies such as Optima, BOSCH and Mediseal.

Products manufactured

Products owned by Pfizer that will be manufactured at the new plant include drugs for the treatment of critical bacterial and fungal infections, as well as therapeutics such as cardiovascular, inflammatory and cancer-related diseases.

Contractors involved

Designer of complex industrial facilities M+W Group was selected as the architect for the pharmaceutical plant.

Marketing commentary on NovaMedica

NovaMedica was established in 2012 by Russian venture capital firm RUSNANO and US venture capital firm Domain Associates.

NovaMedica’s research and development (R&D) department plans to develop 15 innovative drugs by 2022 for the treatment of neurological, ophthalmological and gastroenterological diseases. The company is anticipated to further expand production of injectable products such as pre-filled syringes and disposable infusion bags based on the requirement and high demand for these products in the region.

Estimated investments in NovaMedica projects by its shareholders and foreign investors are expected to be more than $200m over the next five years.

Related Projects